13th International Conference on Cerebral Vascular Biology (CVB 2019) is organized by Well-Assembled Meetings and will be held from Jun 25 - 28, 2019 at Miami Marriott Biscayne Bay, Miami, Florida, United States of America.
Credit Designation Statement
Amedco LLC designates this live activity for a maximum of 20.50 AMA PRA Category 1 Credits for physicians and 20.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.
CVB 2019 will be a forum for scientists from around the world to discuss their cutting edge research on CNS barriers, particularly the blood- brain barrier (BBB) and blood-cerebrospinal fluid-barrier (BCSFB). This will be the continuation of a very successful conference series that was initiated in 1992. The last three conferences took place in Montreal, Canada (2013); Paris, France (2015); and Melbourne, Australia (2017). The CVB conference is returning to the US after 16 years of absence as the most important conference related to cerebral vascular biology. The participants will discuss current and future research surrounding cerebral vascular biology, including development of the brain barriers, drug transport and delivery across the BBB and BCSFB, the role of brain barriers in the etiology and pathology of neurological diseases, and therapeutic strategies to reverse these diseases by targeting the BBB and BCSFB. The emphases will be placed on novel nanotechnologies of drug delivery into the brain and clinical research on disorders involving cerebral vasculature.
This exciting program will therefore attract national and international delegates with an interest in vascular biology, pharmacology, neuroscience and pharmaceutical science, all with the ultimate aim of promoting the brain barriers as key in maintaining brain homeostasis and contributing to disease processes. Active participation of trainees and minorities will be strongly encouraged.
The overall objective/goal of CVB 2019 is to serve as a catalyst for exchange of information on the latest scientific discoveries related to gene therapy in the brain, the bioengineering of the BBB, efficient drug delivery into the brain, and involvement of the BBB in the physiology and pathology of the brain.
Specific objectives are:
• Promote the clinical translation of basic scientific discoveries by communicating and disseminating research findings.
• Provide a forum at which scientists, clinicians, and trainees can interact and exchange novel ideas in order to identify innovative and translational research for a more efficient treatment.
• Promote inclusion and diversity, and engage trainees and early career stage investigators in the field of cerebral vascular biology.
Additional details will be posted as soon as they are available.
|Contact No. :||(503) 635-4761
|Registration Type||End Date||Price|
|Scientist/Faculty/Clinician Late Fee||25 Jun,2019||USD 750.00|
|Postdoctoral Scholar/Fellow Late Fee||25 Jun,2019||USD 550.00|
|Student late Fee||25 Jun,2019||USD 450.00|
|Industrial representative Late Fee||25 Jun,2019||USD 1050.00|